NS Pharma

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, NS Pharma sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 3 currently recruiting 6 completed early-phase tilt top decile by trial count

NS Pharma: 11 sponsored US clinical trials, 3 recruiting.

NS Pharma sponsors 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Duchenne Muscular Dystrophy, with 4 trials.

Top-decile sponsor footprint

NS Pharma ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1

NS-050/NCNP-03 in Boys With DMD (Meteor50)

NCT06053814
RECRUITING Phase 2

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT05996003
RECRUITING Phase 2

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222
ACTIVE NOT RECRUITING Phase 4

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

NCT04687020
TERMINATED Phase 2

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

NCT04854096
COMPLETED Phase 2

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

NCT04956289
COMPLETED Phase 3

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

NCT04060199
COMPLETED Phase 2

Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT03167255
COMPLETED Phase 2

Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02740972
COMPLETED Phase 1

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

NCT01423851
COMPLETED Phase 1

Study of NS-9 in Patients With Liver Metastases

NCT00094003

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6
Phase 3 1
Phase 4 1

Therapeutic Areas

Duchenne Muscular Dystrophy 4
Exon 44 1
Post-Polycythemia Vera Myelofibrosis 1
Post-Essential Thrombocythemia Myelofibrosis 1
DMD 1
Churg-Strauss Syndrome 1
Eosinophilic Granulomatosis With Polyangiitis 1
Primary Myelofibrosis 1

What is open in the NS Pharma pipeline

3 recruiting of 11 indexed (27% open); 6 completed (55%).

Phase mix: 2 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Duchenne Muscular Dystrophy (4 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

NS Pharma: open-pipeline peers nationwide

Peers matched on 11 registered trials and 27% open enrollment, not the therapeutic-area sidebar.

NS Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30% Total trials Recruiting share NS PharmaAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeConnecticut Children's Medical CenterCriteriumMinneapolis Heart Institute FoundationNerviano Medical Sciences
NS Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

NS Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 27% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this NS Pharma page

11 registered trials is a research-attention snapshot, not an endorsement of NS Pharma or any single study.

  • 3 of NS Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Duchenne Muscular Dystrophy is the condition NS Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Duchenne Muscular Dystrophy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. NS Pharma pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.